3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
2
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
203
Brain Neoplasms
94
Gliosarcoma
93
Glioma
88
Central Nervous System Neoplasms
78
Astrocytoma
66
Oligodendroglioma
45
Melanoma
37
Medulloblastoma
18
Neuroblastoma
17
Neoplasm Metastasis
14
Ependymoma
13
Neoplasms
10
Choroid Plexus Neoplasms
10
Sarcoma
9
Recurrence
9
Optic Nerve Glioma
9
Familial ependymoma
9
Carcinoma, Non-Small-Cell Lung
9
Ovarian Neoplasms
8
Lung Neoplasms
8
Spinal Cord Neoplasms
7
Breast Neoplasms
7
Uveal Melanoma
6
Sarcoma, Ewing
6
Rhabdoid Tumor
6
Pinealoma
6
Neuroectodermal Tumors, Primitive
6
Unspecified Adult Solid Tumor, Protocol Specific
5
Small Cell Lung Carcinoma
5
Interventions
Bevacizumab
3
Radiosurgery
2
Irinotecan
2
pembrolizumab
1
Vorinostat
1
Valproic Acid
1
Thalidomide
1
Temozolomide
1
Surveys and Questionnaires
1
Sorafenib
1
Sildenafil Citrate
1
Pliability
1
Nivolumab
1
Morphine
1
Methadone
1
Exercise
1
Equipment and Supplies
1
Eating
1
Carboplatin
1
Amifampridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neurologic Manifestations
×
Temozolomide
×
Clear all
NCT01120639
2021-08-06
Tx-Treatment
Stanford University
Phase 1/2
Completed
30 enrolled
19 charts